

NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

10th February 2021

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager-Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on 10th February 2021, has approved the following

1. Statement of unaudited financial results, (Standalone) for the quarter and nine month ended 31st December 2020. (Annexure-I)
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II).
3. Appointment of Mr. Madhukar Deshpande (DIN-07630081) as Independent Director (Additional) with immediate effect. (Annexure-III).
4. Reconstitution of Committees. (Annexure-IV)


The Meeting Commenced on 01:00 p.m. and Concluded on 04:00 p.m.

The above information will be made available on the Company's website www.nathbiogenes.com.

You are requested to take the above information on record.

Thanking You

Yours faithfully,
For Nath Bio-Genes (India) Limited


Devinder Khurana
Chief Financial Officer



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31/12/2020

Rs in Lacs

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2020 Unaudited	30/09/2020 Unaudited	31/12/2019 Unaudited	31/12/2020 Unaudited	31/12/2019 Unaudited	31/03/2020 Audited
I	Income						
	(a) Revenue from operations	3603.08	2326.38	3305.76	25254.54	21974.12	27989.05
	(b) Other Operating Income	92.79	45.14	38.12	177.49	133.48	182.25
	Total Income	3695.86	2371.52	3343.88	25432.03	22107.61	28171.30
II	Expenses						
	a) Cost of Material Consumed	2620.35	3441.63	4870.42	10332.17	10987.39	16714.88
	b) Purchase of Stock-in-Trade	73.36	452.64	241.95	538.53	400.00	734.82
	c) Changes in Inventory of Finished Goods & Work in Progress	(1553.65)	(3598.18)	(4050.44)	339.36	(1846.13)	(4824.61)
	d) Employee Benefit Expense	493.97	398.19	515.45	1400.95	1252.02	1873.72
	e) Finance Costs	209.91	201.40	163.38	608.87	485.12	654.60
	f) Depreciation & Amortisation Expenses	67.24	67.17	37.75	201.06	110.25	145.26
	g) Selling & Distribution Expenses	716.54	570.22	604.62	5306.21	4803.90	5948.29
	h) Admin & R&D Expenditure	614.16	522.00	554.24	1779.22	1581.45	2073.50
	Total Expenses	3241.88	2055.06	2937.37	20506.38	17774.00	23320.45
III	Profit before Exceptional Items & Tax (I - II)	453.98	316.46	406.51	4925.65	4333.61	4850.85
IV	Exceptional Items Income/(Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
V	Profit Before Tax (III+IV)	453.98	316.46	406.51	4925.65	4333.61	4850.85
VI	Tax Expense						
	(a) Current Tax	29.24	15.08	16.13	73.78	42.60	16.06
	(b) Earlier Year Tax	0.00	0.00	0.00	0.00	5.78	(216.65)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	3.03
VII	Net Profit for the period (V-VI)	424.74	301.38	390.37	4851.87	4285.23	5048.40
VIII	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	44.75
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	44.75
IX	Total Comprehensive Income for the period (VII + VIII)	424.74	301.38	390.37	4851.87	4285.23	5003.65
X	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XI	Reserves (excluding Revaluation Reserves) as per balance sheet of previous	58713.19	58288.45	53142.90	58713.19	53142.90	53861.32
XII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	2.23	1.59	2.05	25.53	22.55	26.33

NOTES:

- (1) The financial results were reviewed by the Audit Committee in meeting held on 08 February 2021 and were thereafter approved by the Board of Directors at its meeting held on 10 February 2021.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation.
- (3) There was no major impact of COVID 19 on operations of the Company. The plants were operational with special permission from the appropriate authorities. However, the production and logistics were affected to certain extent. Market also felt the brunt of Pandemic due to restricted lifting of material.
- (4) The figures have been regrouped/rearranged where ever necessary.


FOR NATH BIO-GENES (INDIA) LTD

Satish Kagiwar
Satish Kagiwar
MANAGING DIRECTOR
DIN 00119601

Place : Aurangabad

Date : 10 Feb 2021

Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)
www.nathbiogenes.com



ASHOK R. MAJETHIA

BCom. F.C.A
CHARTERED ACCOUNTANT

Ashok R. Majethia & Co.
Chartered Accountants
Utsav Complex,
Office No. 7, Bazar Peth,
Dist. Raigad, Khopoli – 410 203
Tel :- (02192) 269908
Mobile :- 9404711539 / 9372169952
Email :- ashokmajethia@rediffmail.com

LIMITED REVIEW REPORT


To,
The Board of Directors
Nath Bio-Genes (India) Limited
Aurangabad

1. We have reviewed the accompanying statement of unaudited financial results of Nath Bio-Genes (India) Limited for the quarter ended 31st December, 2020 and year to date results for the period 1st April 2020 to 31st December 2020 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ashok R Majethia
Chartered Accountants
FRN: 127769XX


Ashok R Majethia
Proprietor


M No: 124781

UDIN: 21124781AAAAAD8227



Place: Aurangabad

Date: 10th February, 2021



NATH SEEDS®

Nath Bio-Genes (I) Ltd.


(CIN L01110MH1993PLC072842)

Annexure- (III)

Nath Bio Genes (India) Limited


Appointment of Mr. Madhukar Deshpande (DIN-07630081) as Independent Director (additional).

Date of Appointment	10 th February 2021
Designation	Independent Director (additional)
Terms and Condition	Regular
Brief Profile and Experiences	<p>Mr. Deshpande an agriculturist, is an individual of immense potential he is Commerce Graduate.</p> <p>He has over 37 years of rich experience in the field of Agriculture, and Management with various companies in agriculture sector.</p> <p>He is also having Immense experience in the field of Processing, Store, Logistics, Quality Assurance and of Production Department with Various Industries.</p>
Qualification	Graduate



- Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com
- 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

**NATH
GROUP**



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

(Annexure-IV)

Reconstitution of Committees.

Reconstitution of Committees as follows.

1. Audit Committee

Sr. No	Name of Committee Member
1	Mr. Madhukar Deshpande- Chairperson
2	Mr. Vadla Nagbhushanam -Member
3	Mr. Satish Kagliwal -Member

2. Stakeholders Relationship Committee.

Sr. No	Name of Committee Member
1	Mr. Madhukar Deshpande- Chairperson
2	Mr. Vadla Nagbhushanam -Member
3	Mr. Satish Kagliwal -Member

3. Nomination and Remuneration Committee.

Sr. No	Name of Committee Member
1	Mr. Shrirang Agrawal- Chairperson
2	Mr. Vadla Nagbhushanam -Member
3	Mr. Madhukar Deshpande- Member

4. Corporate Social Responsibility Committee

Sr. No	Name of Committee Member
1	Mr. Vadla Nagbhushanam -Chairperson
2	Mr. Satish Kagliwal-Member
3	Mr. Madhukar Deshpande- Member

